About
NeuroHagana (NH) develops an injectable emergency treatment for neurotrauma, irrespective of its type or severity. The novel treatment acts immediately to protect against the main factor in Neurotrauma pathology: Glutamate Excitotoxicity.
NH’s technology has been pre-clinically validated in animal models of Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion, with no side effects. The new treatment reduces the toxic impact of excessive Glutamate levels in the Central Nervous System, preventing irreversible neuronal damage and physical disabilities. First applications will be Spinal Cord Injury, first in Europe and USA. Other applications will be Traumatic Brain Injury and Stroke.
Essential for paramedics, hospital trauma units, first aid teams and military forces, the new innovative drug aims to become a vital component of any core emergency kit, preventing permanent disabilities of the injured people and giving them the opportunity to regain their freedom.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was NeuroHagana founded?
- NeuroHagana was founded in March 2023.
- What is NeuroHagana's primary focus?
- NeuroHagana develops an injectable emergency treatment for neurotrauma, aiming to prevent permanent disabilities by protecting against Glutamate Excitotoxicity.
- What is the current stage of NeuroHagana's product development?
- NeuroHagana's product is currently in the R&D stage, with pre-clinical validation in animal models for Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion.
- What are the initial target applications for NeuroHagana's treatment?
- The first applications for NeuroHagana's treatment will be Spinal Cord Injury, initially in Europe and the USA, followed by Traumatic Brain Injury and Stroke.
- How many employees does NeuroHagana currently have?
- NeuroHagana currently has 5 employees.
- What is NeuroHagana's current funding stage?
- NeuroHagana is currently in the Pre-Funding stage.
- Has NeuroHagana been recognized by any incubators or programs?
- Yes, NeuroHagana was part of the SCI Incubate 2025 Cohort by Praxis Spinal Cord Institute, as announced on May 28, 2025.
- Who are the co-founders of NeuroHagana?
- The co-founders of NeuroHagana are Angela Ruban and Dani Schaumann.